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A B S T R A C T
Background
Clinicians typically select the antibiotics used to treat pulmonary infections in people with cystic fibrosis based on the results of
antimicrobial susceptibility testing performed on bacteria traditionally grown in a planktonic mode (grown in a liquid). However, there is
considerable evidence to suggest that Pseudomonas aeruginosa actually grows in a biofilm (or slime layer) in the airways of people with
cystic fibrosis with chronic pulmonary infections. Therefore, choosing antibiotics based on biofilm rather than conventional antimicrobial
susceptibility testing could potentially improve response to treatment of Pseudomonas aeruginosa in people with cystic fibrosis. This is an
update of a previously published Cochrane Review.
Objectives
To compare biofilm antimicrobial susceptibility testing-driven therapy to conventional antimicrobial susceptibility testing-driven therapy
in the treatment of Pseudomonas aeruginosa infection in people with cystic fibrosis.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and
conference abstract books. Most recent search: 07 April 2020.
We also searched two ongoing trials registries and the reference lists of relevant articles and reviews. Most recent searches: 07 April 2020
and 05 September 2017.
Selection criteria
Randomized controlled trials (RCTs) of antibiotic therapy based on biofilm antimicrobial susceptibility testing compared to antibiotic
therapy based on conventional antimicrobial susceptibility testing in the treatment of Pseudomonas aeruginosa pulmonary infection in
people with cystic fibrosis.
Data collection and analysis
Two authors independently selected RCTs, assessed their risk of bias and extracted data from eligible trials. Additionally, the review authors
contacted the trial investigators to obtain further information. The quality of the evidence was assessed using the GRADE criteria.
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Main results
The searches identified two multicentre, double-blind RCTs eligible for inclusion in the review with a total of 78 participants (adults and
children); one RCT was undertaken in people who were clinically stable, the second was in people experiencing pulmonary exacerbations.
Both RCTs prospectively assessed whether the use of biofilm antimicrobial susceptibility testing improved microbiological and clinical
outcomes in participants with cystic fibrosis who were infected with Pseudomonas aeruginosa. The primary outcome was the change in
sputum Pseudomonas aeruginosa density from the beginning to the end of antibiotic therapy.
Although the intervention was shown to be safe, the data from these two RCTs did not provide evidence that biofilm susceptibility testing
was superior to conventional susceptibility testing either in terms of microbiological or lung function outcomes. One of the trials also
measured risk and time to subsequent exacerbation as well as quality of life measures and did not demonstrate any diKerence between
groups in these outcomes. Both RCTs had an overall low risk of bias and the quality of the evidence using GRADE criteria was deemed to
be moderate to high for the outcomes selected.
Authors' conclusions
The current evidence is insuKicient to recommend choosing antibiotics based on biofilm antimicrobial susceptibility testing rather than
conventional antimicrobial susceptibility testing in the treatment of Pseudomonas aeruginosa pulmonary infections in people with cystic
fibrosis. Biofilm antimicrobial susceptibility testing may be more appropriate in the development of newer, more eKective formulations
of drugs which can then be tested in clinical trials.
P L A I N   L A N G U A G E   S U M M A R Y
Standard versus biofilm antibiotic testing to guide antibiotic treatment in cystic fibrosis
Review question
We reviewed evidence to see which testing method is better when deciding which antibiotics to use for treating a flare up of symptoms
in people with cystic fibrosis; whether it is better to test antibiotics on Pseudomonas aeruginosa bacteria (bugs) when they are grown in
a layer of slime (a biofilm) or when they are grown in liquid. We wanted to know if one of these methods would lead to better antibiotic
choices with better clinical outcomes.
Background
Long-term lung infection is the main cause of death in people with cystic fibrosis. Antibiotic treatments for these infections have helped
people with cystic fibrosis live longer. Doctors usually choose which antibiotics to use aLer on testing them against bacteria grown from
samples taken from the infected person. These bacteria are grown in a liquid in the laboratory; but in real life bacteria such as Pseudomonas
aeruginosa do not grow in liquid in the lungs of people with cystic fibrosis, instead they grow in a slime layer called a biofilm. Laboratory
testing of antibiotics against Pseudomonas aeruginosa grown in a biofilm rather than in a liquid may give results that lead to better
antibiotic choices with better clinical outcomes when treating lung infections in people with cystic fibrosis.
Search date
We last looked for evidence on 07 April 2020.
Study characteristics
We included two trials, one run in the USA (in people who were clinically stable) and one run in Canada (in people who were having an
exacerbation or respiratory flare up). A total of 78 people from these trials gave sputum samples. Bacteria from these samples were grown
in either a liquid (34 samples) or biofilm (44 samples) with an equal chance of being grown in either one. Neither the people taking part
or their clinicians knew before or during the trial which method had been used for the sample from each person. A mixture of adults and
children took part in the trials, with the average age being around 20 to 30 years. There were an equal number of men and women in both
trials. Around half the people in the trials had two copies of the delta F508 gene and there were almost equal number of these in each
group. Average lung function in both groups was similar.
Key results
The main outcome of both trials was the decrease in the amount of bacteria in the sputum of people in each group aLer antibiotic
treatment. There was no diKerence in the levels of bacteria found in the sputum or in the improvement in lung function between the two
groups in either trial. In both trials, there was a similar number of individuals in each group who had either a mild or moderate side eKect.
There were no serious side eKects reported by anyone in either study. The evidence does not show that one method of testing is better
than the other and that people receiving antibiotics chosen on the basis of either method have equal chances of any side eKects.
Quality of the evidence
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis (Review)









Cochrane Database of Systematic Reviews
The quality of the evidence was quite good as people had equal chances of being in either group and they did not know which testing
group they were in. This means we don't think the trial results would have been aKected because of this.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Summary of findings
Biofilm antimicrobial susceptibility testing compared with standard antimicrobial susceptibility testing for guiding antibiotic therapy in cystic fibrosis
Patient or population: adults and children with cystic fibrosis and P aeruginosa
Settings: outpatients
Intervention: antibiotics chosen on the basis of biofilm antimicrobial susceptibility testing
Comparison: antibiotics chosen on the basis of standard antimicrobial susceptibility testing



















FEV1 change from start of
treatment (L)
Follow-up: 14 days
The mean change in FEV1 ranged














FEV1 change from start of
treatment (% predicted)
Follow-up: 14 days
The mean (SD) change in FEV1 in the













Data provided by the
authors for this out-
come.
Time to next exacerbation
Follow-up: 5 years
The median time to subsequent exacerbation was 185
days in the standard testing group and 162 days in the
biofilm group. The difference in survival curves was not


























































































































































The HR for subsequent exacerbation also showed no sig-
nificant difference between groups, HR 0.54 (95% CI 0.25
to 1.16).
Adverse events: number of
moderate adverse events
Follow-up: duration of antibiot-
ic treatment (14 days)








There was no signifi-
cant difference in the
number of mild events
between standard or
biofilm groups.
There were no severe
adverse events ob-
served in either group.




The mean change in sputum densi-
ty ranged across control groups from


















change in CFQ-R score from
start of treatment
Follow-up: 14 days
The mean change in CFQ-R score in the
control group was 26.39 points.
The mean
change in CFQ-












There was a significant
difference in change
in CFQ-R scores be-




*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CFQ-R: Cystic Fibrosis Questionnaire - Revised; CFU: colony forming units; CI: confidence interval; FEV 1: forced expiratory volume in 1 second; HR: hazard ratio; P aerugi-
nosa : Pseudomonas aeruginosa; RR: risk ratio; SD: standard deviation.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.





















































































































































Very low quality: we are very uncertain about the estimate.
a Downgraded once due to small number of participants from 1 trial.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common life-limiting genetic
disorder in populations of Northern European descent (Farrell
2018). The leading cause of death in CF is respiratory failure
secondary to chronic bacterial respiratory infection (Gibson 2003).
One of the most important bacteria that infect the airways of
people with CF is Pseudomonas aeruginosa (Burns 2001; Henry
1992; Kosorok 2001; Pamukcu 1995). More aggressive use of
antibiotic therapy to treat these infections is considered to be
an important factor for the improved survival seen in people
with CF (Frederiksen 1996; Ramsey 1996). Typically the antibiotics
used to treat pulmonary infections in CF are chosen based on
the results of laboratory testing of the antimicrobial susceptibility
(Waters 2008). Acute pulmonary exacerbations are typically treated
with intravenous antibiotics for 14 days, although the length of
antibiotic treatment may vary.
Description of the intervention
In the laboratory, bacteria are cultured from the respiratory tract
specimens from people with CF. Traditionally, the bacteria are
then grown in a planktonic mode (grown in a liquid) and exposed
to fixed concentrations of diKerent antibiotics (Jorgensen 2009).
The potential eKicacy of antibiotics is determined by measuring
their ability to inhibit the growth of these bacteria, leading to
each bacterium being graded as susceptible, intermediate or
resistant to each tested antibiotic. Clinicians choose antibiotics to
which the bacterium is susceptible for treating their patients. This
type of conventional antimicrobial susceptibility testing based on
planktonic growth of bacteria has been validated in the treatment
of urinary tract and blood stream infections, in which susceptibility
results correlate well with clinical outcomes (MacGowan 2008).
This is not the case for the treatment of pulmonary infections
in CF (Gilligan 2006). Trials have shown that, in terms of
lung function, there is no association between conventional
antimicrobial susceptibility results and clinical outcomes following
the administration of antibiotics for a pulmonary exacerbation
(Smith 2003). In addition, susceptibility testing is typically
performed on one colony selected from a similar appearing growth
of an organism (morphotype). However, diKerent colonies from the
same morphotype of P aeruginosa grown from e.g. a CF sputum
sample, may have diKerent antimicrobial susceptibility results,
making it diKicult to evaluate the role of conventional susceptibility
testing in CF (Foweraker 2005).
In fact, there is considerable in vitro and in vivo evidence to
suggest that P aeruginosa actually grows in a biofilm (or slime
layer) in the airways of people with CF with chronic pulmonary
infections (Murray 2007; Drenkard 2002; Singh 2000). Biofilms
are communities of bacteria embedded in an exopolysaccharide
matrix (coating of sugar molecules) that make them more resistant
to antimicrobial killing (Prince 2002). In the laboratory, bacteria
are usually grown as a biofilm by growing them on plastic pegs
(Ceri 1999). In order to perform biofilm antimicrobial susceptibility
testing, the bacteria are then exposed to antibiotics by placing
the plastic pegs into wells (usually in a 96-well plate) containing
diKerent antibiotics at fixed concentrations. The ability of the
antibiotic to inhibit or kill the bacteria in a biofilm can be
determined by a variety of methods. There are limitations to this
system however. In contrast to this assay (or test) that grows P
aeruginosa on plastic pegs, trials have shown that P aeruginosa
actually forms a biofilm within the mucous itself (Bjarnsholt 2009).
In addition, in this assay, P aeruginosa is grown under aerobic
conditions but there is considerable evidence that organisms grow
within an anaerobic environment in the CF lung (Tielen 2010).
Biofilm antimicrobial susceptibility testing has generally been
performed in research settings. There is, however, a commercially
available biofilm antimicrobial susceptibility panel, called BioFILM
PA™ (Innovotech Inc), which is licensed by Health Canada for
antimicrobial susceptibility testing of P aeruginosa.
How the intervention might work
It would therefore seem logical to expect that antimicrobial
susceptibilities determined for bacteria growing as a biofilm,
rather than planktonically, would lead to more reliable antibiotic
choices in treating P aeruginosa in the CF airway. Previously,
the use of biofilm susceptibility assays for isolates of P
aeruginosa from people with CF have shown that antimicrobial
susceptibilities based on biofilm growth diKer significantly
from those based on planktonic growth. In one trial, biofilm
inhibitory concentrations (concentrations of antibiotics that inhibit
biofilm growth) for P aeruginosa were much higher than the
corresponding conventionally determined minimum inhibitory
concentrations (MICs) for several classes of antibiotics including ß-
lactams (Moskowitz 2004), leading to diKerent simulated antibiotic
regimens (Moskowitz 2005). Using a similar biofilm antimicrobial
susceptibility assay, the Calgary Biofilm Device, minimal biofilm
eradication concentrations of selected antibiotics were found to
be 100 to 1000 times the MICs for certain organisms including P
aeruginosa (Ceri 1999). Hence, antibiotic susceptibilities based on
biofilm-grown P aeruginosa may lead to diKerent antibiotic choices
with potentially improved microbiological and clinical outcomes.
Why it is important to do this review
Antibiotic therapy plays an important part in maintaining the
health and longevity of people with CF. However, there is
currently no way of choosing antibiotic therapy in CF that is
proven to result in improved clinical outcomes. Conventional
antimicrobial susceptibility testing may not accurately reflect
how bacteria grow in the CF lung; biofilm antimicrobial
susceptibility testing may be a better methodology, leading
to improved clinical outcomes and fewer adverse eKects. To
answer this question, this review compared therapy driven by
biofilm antimicrobial susceptibility testing to therapy driven by
conventional antimicrobial susceptibility testing for treating P
aeruginosa infection in people with CF.
This is an updated version of a previously published Cochrane
Review (Waters 2012; Waters 2015; Waters 2017).
O B J E C T I V E S
To compare biofilm antimicrobial susceptibility testing-driven
therapy to conventional antimicrobial susceptibility testing-driven
therapy in the treatment of P aeruginosa infection in people with
CF.
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis (Review)
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Adults and children (with all levels of disease severity) diagnosed
with CF, confirmed with sweat test or genetic testing (or both),
who have P aeruginosa isolated from respiratory specimens.
Respiratory tract specimens include sputum, throat swabs or
bronchoalveolar lavage specimens.
Types of interventions
Antibiotic therapy driven by biofilm antimicrobial susceptibility
testing compared to antibiotic therapy driven by conventional
antimicrobial susceptibility testing for treating of P aeruginosa
infection in people with CF. Antibiotic therapy includes single or
multiple antibiotics, oral, inhaled or intravenous antibiotics.
Types of outcome measures
Primary outcomes
1. Lung function
a. forced expiratory volume at one second (FEV1) (absolute
values or change from start of treatment (post hoc change) (L
or per cent (%) predicted or both))
b. forced vital capacity (FVC) (absolute values or change from
start of treatment (post hoc change) (L or % predicted or
both))
c. mid-expiratory flow (FEF25-75%) (absolute values or change
from start of treatment (post hoc change) (L or % predicted
or both))
2. Pulmonary exacerbations, defined as an increase in respiratory
symptoms requiring antibiotic therapy (Fuchs 1994)
a. number of pulmonary exacerbations
b. time between pulmonary exacerbations
c. time to subsequent exacerbation
3. Adverse events (including numbers of events, proportion
of participants withdrawing and proportion of participants
changing therapy)
a. mild (transient event, no treatment change, e.g. rash)
b. moderate (treatment discontinued, e.g. nephrotoxicity)
c. severe (causing hospitalization or death)
Secondary outcomes
1. Sputum bacterial density (measured in colony forming units/ml
(CFU/mL))
2. Quality of life (QoL) (as measured by a validated QoL score i.e.





c. body mass index (BMI)
5. Number of hospitalizations
Search methods for identification of studies
We searched for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
We identified relevant trials from the Group's Cystic Fibrosis Trials
Register using the terms: antibiotics susceptibility (sensitivity)
testing.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis
conferences: the International Cystic Fibrosis Conference; the
European Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for the
register, please see the relevant sections of the website.
Date of last search of the Group's Cystic Fibrosis Trials Register: 07
April 2020.
We also checked the National Institutes of Health (NIH) sponsored
website www.clinicaltrials.govfor any ongoing trials with potential
interim results using the search terms 'cystic fibrosis' and 'biofilm'.
Most recent search: 07 April 2020.
We searched the WHO ICTRP (apps.who.int/trialsearch/
default.aspx) using the terms 'cystic fibrosis' and 'biofilm'. Most
recent search: 05 September 2017*.
*For update 2020, this database is not currently available due to
Covid-19.
Searching other resources
We checked the reference lists of all trials identified for any further
relevant trials. We also contacted biotech companies that are
involved with biofilm antimicrobial susceptibility technology for
any additional information.
Data collection and analysis
Selection of studies
For the initial review and subsequent updates until 2020, two
authors (VW, FR) independently applied the inclusion criteria to
all potential trials; for the current version of the review the two
authors were SS and NJ. The authors were not blinded to the trials.
If a disagreement had occurred, the authors would have resolved
this by discussion with a third person (NJ for review versions up
to 2020 or FR for the 2020 update). For one trial on which the two
review authors were co-investigators (Yau 2014), NJ and the Cystic
Fibrosis and Genetic Disorders Group's statistician Sarah Nolan (SN)
confirmed eligibility for inclusion.
Data extraction and management
Using a data collection form, two authors (VW, FR) independently
recorded data for the Moskowitz trial which they obtained from
published reports or from trial investigators. If a disagreement had
occurred, they would have resolved it by discussion with a third
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis (Review)
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person (NJ). For the Yau trial included at the 2015 update in which
both review authors were active investigators, NJ and SN extracted
data. In addition to information about trial references, authors and
verification of trial eligibility, the data collection form included
information about the methods of the trial (e.g. trial duration,
type of trial (e.g. RCT), blinding, number of dropouts and potential
confounders). The authors also reported characteristics of the trial
participants including age, sex and setting of the trial on the form.
Furthermore, they also described the intervention with regards to
type of antibiotic, route of delivery, doses and length of treatment.
The authors collected data for all randomized participants. The
authors attempted to collect the following data: the mean change
(before and aLer antibiotic therapy) in FEV1 and FVC, FEF25-75%;
the mean hospital length of stay and number of hospitalizations;
the time to subsequent pulmonary exacerbation; the number
of adverse events; the mean QoL score aLer antibiotic therapy;
the mean change in sputum bacterial density (before and aLer
antibiotic therapy); the number of mortalities; change in weight
(before and aLer antibiotic therapy); and the number of days of oral
antibiotic use. For each mean value, the authors also obtained the
standard deviation (SD) (variation from the average). For time-to-
next exacerbation, they tried to obtain log-rank estimates and Cox
model estimates.
The authors planned to measure outcomes at less than a week,
one to two weeks, more than two weeks to three weeks, more than
three weeks to four weeks and at monthly intervals, if applicable.
They have actually reported data at Day 7, Day 14 and one month.
They would have measured the outcome 'Time to next pulmonary
exacerbation' in monthly intervals aLer these time points; however
given the data which are available from the Yau trial (Yau 2014), they
have reported this outcome as a hazard ratio (HR) in days. In future
updates, they will also consider outcomes measured at other time
points.
Assessment of risk of bias in included studies
Two authors (VW, FR) independently assessed the Moskowitz trial
for the following types of bias: selection bias (bias in choosing
trial participants); performance bias (bias in the care of trial
participants); attrition bias (bias in how participants who are lost
to follow up are handled); detection bias (biased assessment
of outcome); and reporting bias (bias in the reporting of trial
outcomes) using the following strategies as outlined below (Higgins
2011). For the Yau trial, NJ and SN assessed the risks of bias since
VW and FR were active investigators on the trial (Yau 2014).
Assessment of generation of allocation sequences
They assessed each trial as to the generation of allocation
sequences:
1. low risk of bias: if allocation sequence is suitable to prevent
selection bias (i.e. random numbers table, drawing envelopes,
tossing a coin, throwing dice, etc);
2. high risk of bias: if allocation sequence could be related to
prognosis and thus introduce selection bias (i.e. assigning
participants based on case record number, date of birth, date of
admission, etc);
3. unclear risk of bias: if the trial is described as randomised but the
method used to generate the allocation sequence is not stated.
Assessment of concealment of allocation sequences
They also assessed the method used to conceal the allocation
sequences in each trial:
1. low risk of bias: if participants and investigators cannot predict
which group the participant will be assigned to (i.e. coded drug
containers, central randomisation, numbered, sealed, opaque
envelopes, etc);
2. high risk of bias: if participants and investigators can predict
which group the participant will be assigned to and thus
introduce selection bias (i.e. open allocation schedule, non-
opaque envelopes, etc);
3. unclear risk of bias: if the method of concealing the allocation
sequence is not described.
Assessment of blinding
In order to determine the potential for performance and detection
bias, the authors assessed each trial with respect to the degree of
blinding:
1. the participant is blinded to participant assignment;
2. the care provider is blinded to participant assignment;
3. the investigator measuring trial outcomes is blinded to
participant assignment.
They considered there to be a high risk of bias if there was no
blinding with respect to one or more of the above categories. They
considered there to be a low risk of bias if the trial was blinded
to all three. They considered there to be an unclear risk of bias if
the trial did not specify the degree of blinding in each of the three
categories.
Incomplete outcome data
To assess for the possibility of attrition bias, the authors examined
each trial with respect to:
1. whether or not it was stated how many participants were lost to
follow-up and why they were lost to follow-up;
2. whether or not an intention-to-treat analysis was used (i.e.
inclusion in the final analysis of all randomised participants into
a trial in the groups to which they were randomised irrespective
of what happened subsequently).
They considered there to be a high risk of bias if an intention-to-
treat analysis was not used. They considered there to be a low risk
of bias if the number and reason for loss of follow-up was specified
and if an intention-to-treat analysis was used. They considered
there to be an unclear risk of bias if the trial did not specify the
above outlined information.
Assessment of selective reporting
The authors reviewed the included trials for selective reporting
(Higgins 2011). They compared the original trial protocol with the
published paper to ensure all planned outcomes were reported.
If, for trials the authors may include in the future, the original
trial protocols are not available, they will review the 'Methods'
and 'Results' sections and the authors will use their discretion to
determine if selective reporting has occurred.
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Assessment of other potential sources of bias
The authors also reviewed the included trials for other potential
sources of bias that could have threatened the validity of the
trial. These included: early cessation of the trial; if the interim
results aKect the trial conduct; deviation from the trial protocol;
inappropriate administration of a co-intervention; contamination;
the use of an insensitive instrument to measure outcomes;
selective reporting of subgroups; fraud; inappropriate influence of
funding agencies and industry sponsorship; null bias due to the
interventions being poorly delivered; or the existence of a pre-
randomization of an intervention that could aKect the eKects of the
randomized intervention (Higgins 2011).
Incorporating assessments of trial validity in reviews
For future updates, the authors plan to weigh trials according to
their assessed validity by using the inverse of the variance for the
estimated measure of eKect. If they consider there is a high risk
of bias, they will investigate the eKects of this with a sensitivity
analysis (see below).
Measures of treatment e>ect
For dichotomous data, the review authors gathered information
on participants randomized to each treatment group, based
on an intention-to-treat analysis, and the number of events.
For future updates, they plan to include interim results from
individual randomized participants from ongoing trials in the
analysis. The authors defined time points for each trial outcome
according to when it was measured (see above 'Data extraction and
management'). They analyzed trial outcomes separately according
to these time points. In future updates and if data are available from
multiple trials, they plan to pool the treatment eKect across trials
to determine a risk ratio (RR) and its 95% confidence intervals (CIs)
for each trial outcome.
For continuous data, the authors calculated the diKerence between
the mean (average) values (MD) of treatment eKect for each group.
For future summary statistics across trials, they will use the MD if
the same scale is used, or the standardized mean diKerence (SMD)
if diKerent scales are used (e.g. quality of life measurements) both
with 95% CIs. For time-to-event data, most trials use Kaplan-Meier
survival analysis. The authors will thus collect log-rank estimates
and Cox model estimates to subsequently summarize the time-
to-event data as a HR with 95% CIs (Deeks 2011; Parmar 1998).
Data provided by the investigators on the Yau trial, allowed the
calculation of the log HR and standard error for the outcome 'Time
to next pulmonary exacerbation' which the authors analysed using
the generic inverse variance.
Unit of analysis issues
All analyses were performed at the unit of the participants. In
one trial, participants who experienced an exacerbation during
the study were re-randomised to either conventional or biofilm
antimicrobial susceptibility testing and results were reported at
the unit of analysis of exacerbations rather than participants (Yau
2014). The authors of the trial were able to provide raw data for
the outcomes of interest recorded for this review and SN calculated
results at the unit of the participant.
In future updates, the authors will include data from future
cluster-randomized trials if the information is available. For cluster-
randomized trials, they will calculate the intracluster correlation
coeKicient (ICC) according to Donner (Donner 2001). They will also
include data from cross-over trials if the information is available.
They will analyze continuous data from cross-over trials using one
of three approaches: treat the trial as a parallel trial and pool the
interventional periods and compare these to the pooled placebo
periods; include data from the first period only and approximate
a paired analysis; or impute missing SDs (Sterne 2011). Cross-
over trials with dichotomous outcomes require more complicated
methods and the authors plan to consult with a statistician as
recommended (Elbourne 2002).
Dealing with missing data
Whether or not outcome data are actually collected, in reality, time-
point data are oLen missing for participants who are lost to follow-
up. The authors performed an available-case analysis (analyzing
data for every participant for whom the outcome is obtained) in
these situations. On the data collection form, the authors reported
the proportion of participants from whom no outcome data were
obtained. They only included data on those whose results are
known, using as a denominator the total number of people who
completed the trial for the particular outcome in question. In future,
if the review authors are able to include more trials, they will
consider variations in the degree of missing data across trials as a
potential source of heterogeneity.
Assessment of heterogeneity
For future meta-analyses, the review authors will measure the
variability of results between trials (heterogeneity) using the Chi2
test (where a P value of less than 0.10   indicates the presence of
heterogeneity) (Deeks 2011) and the I2 method outlined by Higgins
(Higgins 2003). The I2 statistic describes the percentage of total
variation across trials that is due to heterogeneity rather than by
chance. It is calculated using Cochran's heterogeneity statistic and
the degrees of freedom. The I2 statistic can range from 0% to 100%.
A value of 0% indicates no observed heterogeneity and larger values
show increasing heterogeneity. A value greater than 50% may be
considered significant heterogeneity.
Assessment of reporting biases
For future updates, to investigate whether this review is subject to
publication bias, the authors will construct a funnel plot, if they
include suKicient trials (at least 10). In the absence of bias, the plot
should resemble a symmetrical inverted funnel (Sterne 2011). If
there is asymmetry, the authors will consider publication bias and
other reasons (such as location biases, true heterogeneity, high risk
of bias of smaller trials, etc.) as a potential cause.
Data synthesis
If the authors consider any trials identified in the future to be
clinically similar enough to combine (e.g. pulmonary exacerbation
trials with diKerent types of antibiotics, oral versus intravenous,
diKerent lengths of treatment), they will investigate statistical
heterogeneity as outlined below. If there is no significant
heterogeneity, they will calculate the pooled eKect estimates using
a fixed-eKect model. If they identify significant heterogeneity (I2
greater than 50%) (Higgins 2003), they will perform a random-
eKects meta-analysis to address heterogeneity among trials.
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis (Review)
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Subgroup analysis and investigation of heterogeneity
In future updates, if there are at least 10 trials included in the
review and if the authors find significant heterogeneity as defined
above (I2 greater than 50%) (Higgins 2003), they will explore
the potential causes of this (i.e. diKerent types of antimicrobial
treatment such as oral, inhaled or intravenous; diKerent participant
populations etc.) and if possible, conduct subgroup analyses
of the trials. For example, trial results may vary if diKerent
types of antibiotic treatments are used (e.g. oral, inhaled or
intravenous) for the treatment of pulmonary infection in diKerent
settings, e.g. acute pulmonary exacerbation or as suppressive
treatment. In addition, results may vary if one trial has more adult
participants able to produce sputum (a more accurate sample
with potentially more reliable culture results) and another trial
has more pediatric participants where only throat swabs are used
(a less reliable respiratory tract sample). Finally, there may be
diKerences depending on whether antibiotics are used to treat
a first-time infection (eradication) versus an established, chronic
infection (over 50% of cultures positive in the previous 12 months).
Sensitivity analysis
If the authors are able to include at least 10 trials in future updates
of the review, they will perform a sensitivity analysis to determine
whether the conclusions are robust to decisions made during the
review process such as the inclusion or exclusion of particular trials
from a meta-analysis, imputing missing data or choice of a method
for analysis. They will investigate whether changing which trials are
included, based on their assessment of the risk of bias (including or
excluding trials with any high risk of bias) or changing their chosen
statistical model (i.e. random-eKects model compared to a fixed-
eKect model) changes the results of the review. If the sensitivity
analysis does not significantly change the results, it strengthens
the confidence that can be placed in these results. The authors will
present the results in an influence plot, as appropriate.
Summary of findings table
In accordance with current Cochrane guidance, we have included
a summary of findings table for the comparison of biofilm testing
versus standard testing (post hoc change at 2017 update). We have
selected the following outcomes which we consider to be the most
important to include.
1. FEV1 (L)
2. FEV1 (% predicted)
3. Time to next exacerbation
4. Adverse events
5. Sputum density
6. Quality of life (CFQ-R)
We have used the GRADE approach to assess the quality of the
evidence for each outcome based on the risk of bias within
the trials, relevance to our population of interest (indirectness),
unexplained heterogeneity or inconsistency, imprecision of the
results or high risk of publication bias. We downgraded the
evidence once if the risk was serious and twice if the risk was
deemed to be very serious.
R E S U L T S
Description of studies
Results of the search
Four trials (18 unique records) were identified in the search. Two
trials (nine records) were excluded (Aaron 2005; Oermann 2010).
Therefore, the search identified two trials (nine records) with data
eligible for inclusion in the review (Moskowitz 2011; Yau 2014).
Included studies
Methods
Both included RCTs were multicenter and double-blind; they
prospectively assessed whether the use of biofilm antimicrobial
susceptibility testing improved microbiological and clinical
outcomes (Moskowitz 2011; Yau 2014). The earlier trial was run
across seven CF centers in the USA (Moskowitz 2011) and the later
trial was run across five CF centers in Canada (Yau 2014).
Participants
Inclusion and exclusion criteria
The earlier trial studied participants with CF who were stable and
infected with P aeruginosa (Moskowitz 2011), while the later trial
enrolled participants with CF who were chronically infected with P
aeruginosa and experiencing a pulmonary exacerbation (Yau 2014).
In the earlier trial, participants were eligible for enrolment
if they had a confirmed diagnosis of CF, were at least 14
years of age, could spontaneously produce sputum, were able
to reliably perform pulmonary function tests, were chronically
infected with P aeruginosa, were clinically stable at the time
of enrolment and provided written consent (Moskowitz 2011).
Chronic infection with P aeruginosa was defined as a history
of persistent P aeruginosa airway infection, defined as any
combination of three or more sputum or bronchoalveolar lavage
fluid cultures positive for P aeruginosa during the 24 months
prior to screening, subsequently amended to allow oropharyngeal
cultures as evidence for persistent infection. The later trial had very
similar inclusion criteria, except that there was no age restriction
for enrolment and participants were experiencing a pulmonary
exacerbation rather than being clinically stable (Yau 2014).
Participants were excluded from the Moskowitz trial if the P
aeruginosa sputum density was less than 105 colony forming
units (CFU)/g at screening, if they were infected with Burkholderia
cepacia complex at screening or in the previous 24 months, if they
were allergic to more than two classes of antibiotics, if they had
received a lung transplantation or if they were pregnant (Moskowitz
2011). It is important to note that the participants had no oral
or inhaled antibiotics within 14 days prior to screening and no
treatment for an acute exacerbation or other administration of
parenteral anti-pseudomonal antibiotics within two months prior
to screening. In the Yau trial, additional exclusion criteria included
being listed for lung transplantation and a decision by the treating
physician to use antibiotics other than those prescribed by the
principal investigator (VW) (Yau 2014).
Enrolled participants
Each RCT enrolled 39 participants (Moskowitz 2011; Yau 2014).
In the Moskowitz trial, 20 were allocated to the biofilm-treated
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group and 19 to the conventionally-treated (control) group
(Moskowitz 2011). In the Yau trial, although the same total
number of participants were randomized, the trial presented data
for more than one randomized exacerbation per participant; 24
participants were randomized to the biofilm-treated group (48
exacerbations) and 15 to the conventionally-treated (control) group
(26 exacerbations) (Yau 2014).
In the Moskowitz trial, the mean (SD) age in the biofilm group was 32
(9.3) years and in the control group was 28.2 (8.6) years (Moskowitz
2011). The participants were slightly younger in the Yau trial; the
mean (range) age in the biofilm group was 29.4 (11.3 to 49.2) years
and in the control group 22.6 (10.1 to 53.2) years (Yau 2014).
Both RCTs reported the gender split of participants. In the
Moskowitz trial, 25 participants were male (16 in the biofilm group
and 9 in the control group) and 14 were female (four in the biofilm
group and 10 in the control group) (Moskowitz 2011). Yau recruited
14 males (11 in the biofilm group and three in the control group)
and 25 females (13 in the biofilm group and 12 in the control group)
(Yau 2014).
In both trials the number of participants homozygous with the
genotype delta F508 was 11 in the biofilm group and nine in the
control group (Moskowitz 2011; Yau 2014).
Both trials reported similar rates of pancreatic insuKiciency;
Moskowitz stated that a total of 34 out of 39 participants were
pancreatic insuKicient (18 in the biofilm group and 16 in the
control group) (Moskowitz 2011) and Yau reported that 35 out of
39 participants were pancreatic insuKicient (22 in the biofilm group
and 13 in the control group) (Yau 2014).
Moskowitz reported the mean (SD) baseline FEV1 % predicted
in participants; in the biofilm group this was 62.2% (23.2) and
in the control group was 64% (28.2) (Moskowitz 2011). Baseline
lung function was slightly lower in the Yau trial; the mean (range)
baseline FEV1 % predicted in the biofilm group was 53.3% (26.8 to
83.9) and 60.6% (25.2 to 98.3) in the control group (Yau 2014).
Interventions
In the Moskowitz trial, clinically stable participants were
randomized to receive a 14-day course of any two antibiotics
(intravenous or oral) chosen on the basis of results from either
conventional or biofilm antimicrobial susceptibility testing of
their P aeruginosa isolate cultured from the sputum obtained
at the screening visit (Moskowitz 2011). In contrast, in the Yau
trial, participants were randomized at the time of a pulmonary
exacerbation requiring intravenous antibiotics. At that time,
enrolled participants were randomized to receive a 14-day course
of two intravenous antibiotics chosen by the primary investigator
(VW) based on the results of either conventional or biofilm
antimicrobial susceptibility testing of their P aeruginosa isolate
cultured from the most recently obtained sputum (Yau 2014).
Outcomes
The primary outcome for the Moskowitz trial was the
microbiological response to antibiotic therapy, measured by the
change in P aeruginosa sputum density, calculated as logarithm10
(log10) of end-of-treatment density minus log10 of screening density
in CFU/g (Moskowitz 2011). The Yau trial also had microbiological
response as the primary outcome but this was determined as the
proportion of exacerbations in the biofilm versus the conventional
group in which a > 3 log10 drop in sputum density of P aeruginosa in
CFU/mL was achieved from day 0 to day 14 of antibiotic treatment.
The change in sputum bacterial density was also calculated in each
group from day 0 to day 14 of antibiotic treatment and to the
one-month follow up, an additional time point not included in the
Moskowitz trial (Yau 2014).
The secondary outcome measure in the Moskowitz trial was
pulmonary response, measured as change in FEV1 L and calculated
as end-of-treatment FEV1 minus the baseline FEV1 (Moskowitz
2011). Secondary outcomes in the Yau trial similarly included
change in pulmonary function tests, measured by both FEV1
and FVC (in L and % predicted), from day 0 to day 14 of
antibiotic treatment to one-month follow-up (Yau 2014). Additional
secondary outcomes in the Yau trial included change in CFQ-
R respiratory scores, serum white blood cell count (WBC), C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR) and
sputum IL-8 and neutrophil elastase measured for all pulmonary
exacerbations in both groups at day 0, day 14 of antibiotic therapy
and at the one-month follow up visit.
Excluded studies
Two trials (nine records) were excluded because they did not
concern the topic of this review; one looked at combination
antibiotic susceptibility testing (Aaron 2005); and the second one
looked at antibiotic susceptibility of P aeruginosa isolates aLer
repeated courses of inhaled aztreonam lysine (Oermann 2010).
Risk of bias in included studies
The overall risk of bias was minimal in the included trials
(Moskowitz 2011; Yau 2014).
Allocation
Sequence generation
In the Moskowitz trial, participants were assigned to treatment
groups using a block randomization procedure, stratified by trial
site, using computer-generated random numbers. Randomization
was done similarly in the Yau study, by computer-generated
random numbers table, stratified by trial site. The allocation of the
intervention was therefore deemed to have a low risk of bias in both
trials (Moskowitz 2011; Yau 2014).
Concealment of allocation
In the Moskowitz trial, randomization assignments were placed in
numbered, sealed envelopes which were opened sequentially at
the time of randomization by the statistician or their designated
representative. The remaining research staK, the participants and
their caregivers were unaware of the allocation. In the Yau trial, the
method of selection was blinded to all participants, treating team
and trial personnel except for the co-principal investigator who
performed the randomization. The concealment of the allocation
was therefore deemed to have a low risk of bias in both trials
(Moskowitz 2011; Yau 2014).
Blinding
In both trials, the person responsible for participant care, the
participant and the outcome assessor were aware of the antibiotic
choices but were blinded to the testing method (biofilm or
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conventional) upon which this choice was based. Therefore, there
was a low risk of performance and detection bias in both studies
(Moskowitz 2011; Yau 2014).
Incomplete outcome data
In the Moskowitz trial, 39 participants were randomized - 20 to
the biofilm-treated group and 19 to the conventionally-treated
(control) group. One participant was randomized but withdrawn
prior to treatment and subsequently re-randomized and treated.
Of the 20 participants who were randomized to the biofilm group,
two withdrew prior to treatment; of the 19 randomized to the
control group, three withdrew prior to treatment. One participant
from each group discontinued treatment due to adverse events.
In the modified intent-to-treat analysis, 18 of the 20 participants
randomized to the biofilm group and 16 of the 19 participants
randomized to the control group were analyzed for FEV1 data; 17
of the 20 in the biofilm group and 14 of the 19 in the control group
were analyzed for sputum density data. Thus, less than 15% of
the participants randomized in the trial were excluded from the
final analysis for lung function data (Moskowitz 2011). In the Yau
trial, of 41 participants randomized, 39 were analyzed. A total of
two participants (5%) were excluded (one from each group) with
no data available for either. One participant from the conventional
group was excluded due to loss to follow up and one participant
was excluded from the biofilm group because there was no growth
of P aeruginosa on Day 1 of treatment (Yau 2014). The risk of
attrition bias for both trials was therefore deemed to be low.
Selective reporting
For the Moskowitz trial, the planned outcome measures
published in the original trial protocol on www.clinicaltrials.gov
(NCT00153634) were almost the same as those reported in the
final manuscript. We believe that any hospitalization data would
likely be collected for safety issues and do not regard the lack of
reporting for this outcome to constitute a risk of bias. However,
with regards to lung function reporting, the trial only reports results
for FEV1, although we would expect the measurements FVC and
FEF25-75% to have been undertaken as part of the standard set of
lung function tests at clinic visits. As we can not be certain that these
tests were definitely undertaken, we judge there to be an unclear
risk of bias with regards to selective reporting (Moskowitz 2011).
For the Yau trial, all the outcomes listed in the protocol accessed
from www.clinicaltrials.gov (NCT00786513) were fully reported in
the paper and the online supplementary materials. Therefore the
Yau trial was deemed to have a low risk of reporting bias (Yau 2014).
Other potential sources of bias
There were no other potential sources of bias identified.
E>ects of interventions




In the Moskowitz trial, FEV1 (L) was measured at the start of
treatment (Day 0) and follow up (Day 14) in 18 participants in the
biofilm group and 16 participants in the control group. In the Yau
trial, FEV1 measurements (in both % predicted and L) were obtained
at Day 0, Day 7, Day 14 of antibiotic treatment and at the one-
month follow up for both groups. We were therefore only able to
combine data from the two trials for the FEV1 (L), change from
start of treatment to Day 14 which produced a combined reported
MD between groups of 0.04 L (95% CI -0.08 to 0.16) (high-quality
evidence) (Analysis 1.1). For the Yau trial, we also analyzed data on
FEV1 for the change from start of treatment to Day 14 measured in
% predicted, MD -2.47% (95% CI -9.29 to 4.34) (Analysis 1.2). The
GRADE quality of evidence was deemed to be moderate for FEV1 %
predicted due to small numbers from one trial.
b. FVC
Data were not reported for this outcome for the Moskowitz trial
(Moskowitz 2011). For the Yau trial, FVC measurements were
obtained at Day 0, Day 7, Day 14 of antibiotic treatment and at the
one-month follow up for both groups (Yau 2014). The change in FVC
% predicted from start of treatment to Day 14 was reported for both
groups, MD -2.27 (95% CI -9.06 to 4.51) (Analysis 1.3); when reported
in L, our analysis showed MD -0.03 L (95% -0.32 to 0.26) (Analysis
1.4).
c. FEF25-75
Data were not reported for this outcome by either trial (Moskowitz
2011; Yau 2014).
2. Pulmonary exacerbations
For the Moskowitz trial, there were no pulmonary exacerbations
in either group during the trial period (Moskowitz 2011). Given
the design of the Yau trial which re-randomized participants
aLer they had experienced an exacerbation, a calculation of
the number of exacerbations by treatment group was not
possible (Yau 2014). However, the time to subsequent pulmonary
exacerbation requiring intravenous antibiotics was calculated for
each randomized exacerbation in both the conventional and
biofilm groups. The median time to subsequent exacerbation was
185 days in the conventional group and 162 days in the biofilm
group; the diKerence in the survival curves was not significant
(P = 0.8, Mantel-Cox test). The HR for subsequent exacerbation
demonstrated no significant diKerence between groups 0.54 (95%
CI 0.25 to 1.16) (Analysis 1.5). In addition, the RR between
groups for developing an exacerbation during the trial period was




In the Moskowitz trial, 12 participants from each group experienced
at least one mild adverse event such as diarrhoea, fatigue,
headache or oral candidiasis, which did not require any treatment
change (Moskowitz 2011). In the Yau trial, there were nine episodes
of mild adverse events in the conventional group and seven
episodes of mild adverse events in the biofilm group that did not
require discontinuation of treatment (Yau 2014). The combined
analysis showed a RR of 0.70 (95% CI 0.48 to 1.04) (Analysis 1.7).
b. moderate
In the Moskowitz trial, one participant from each group experienced
a moderate adverse event that led to discontinuation of treatment
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(Moskowitz 2011). In the Yau trial, there were four pulmonary
exacerbations (three in the conventional group and one in the
biofilm group) in which there were moderate adverse events
leading to discontinuation of the antibiotic (Yau 2014). The
combined RR was 0.36 (95% CI 0.07 to 1.77) (moderate-quality
evidence) (Analysis 1.7).
c. severe
There were no serious adverse events reported (such as death or
hospitalization) in either trial (Analysis 1.7).
Secondary outcomes
1. Sputum bacterial density
In the Moskowitz trial, 17 participants in the biofilm group and
14 participants in the control group had P aeruginosa sputum
density measurements taken at baseline (Day 0) and at follow-up
(Day 14) (Moskowitz 2011). In the Yau trial, sputum P aeruginosa
density measured in log10 CFU/mL was reported for Day 0, Day
14 of antibiotic treatment and at the one-month follow up for all
exacerbations in both groups (Yau 2014). We were therefore able
to combine data from both studies for the change in P aeruginosa
sputum density from start of treatment to Day 14 and report the
MD between groups of 0.80 (95% CI -0.59 to 2.18) (high-quality
evidence) (Analysis 1.8).
2. QoL
Data were not collected for QoL measures in the Moskowitz trial
(Moskowitz 2011). In the Yau trial, respiratory symptom scores
based on the CFQ-R questionnaire were obtained at Day 0, Day
14 of antibiotic treatment and at the one-month follow up for
both groups (Yau 2014). There was a significant diKerence between
groups in the change in CFQ-R scores from start of treatment, MD
-15.04 (95% CI -28.38 to -1.71) at Day 14 and -17.03 (95% CI -30.13
to -3.92) at one month (moderate-quality evidence) (Analysis 1.9).
3. Mortality
There were no deaths reported in either group during either trial
(Moskowitz 2011; Yau 2014).
4. Nutritional parameters
Data were not collected for this outcome for either trial (Moskowitz
2011; Yau 2014).
5. Number of hospitalizations
Data were not collected for this outcome for either trial (Moskowitz
2011; Yau 2014).
D I S C U S S I O N
Summary of main results
The two included RCTs demonstrated that the use of biofilm
antimicrobial susceptibility testing to guide antibiotic treatment of
chronic P aeruginosa infections in people with CF did not result
in a greater decrease in sputum bacterial density or improved
lung function or any diKerence in the time to the next pulmonary
exacerbation or the number of exacerbations (Moskowitz 2011; Yau
2014). There was no diKerence in adverse eKects in either trial; but
one trial did report that QoL scores favoured the standard testing
group (Yau 2014). The major strength of the earlier RCT was its
clinical methodology; it included participants enrolled from seven
CF centers in the USA and both the intervention and control groups
had similar baseline characteristics (Moskowitz 2011). Similarly, the
later RCT was a multicenter (five Canadian sites) trial with an overall
low risk of bias (Yau 2014).
Overall completeness and applicability of evidence
Both included trials studied biofilm antimicrobial susceptibility
testing in both children and adults with CF, under conditions
of clinical stability as well as during pulmonary exacerbations
(Moskowitz 2011; Yau 2014). Both trials used similar experimental
methodologies, growing P aeruginosa biofilms on plastic pegs
and then exposing them to antibiotics in 96 well plates for
24 hours and measuring inhibition of growth. The method by
which antibiotics were chosen, however, was slightly diKerent
between trials. In the Moskowitz trial, antibiotics were chosen
based on the highest ratio of the maximum achievable serum
concentration over the inhibitory concentration whereas in the
Yau trial, susceptible drugs were chosen according to breakpoints
based on systemically achievable antibiotic concentrations as
defined by the Clinical Laboratory Standards Institute (CLSI 2012).
In both instances, though, antibiotic treatment was administered
systemically (either intravenously or orally) and antibiotics choices
based on the lower drug concentrations achievable in serum. In
the end, although preliminary data showed that antibiotic choices
do diKer based on biofilm versus conventional antimicrobial
susceptibility testing (Moskowitz 2005), the antibiotic regimens
in the treatment and control arms were very similar in both
studies. This may be due to an inability to identify more eKective
antibiotics against biofilm-grown organisms at such low drug
concentrations. In addition, the similarity between treatment
regimens may also have been a result of a limited number of
antimicrobial classes with anti-pseudomonal activity. The higher
intrapulmonary concentrations achievable through aerosolization
of antibiotics, such as tobramycin, may be more eKective against
bacterial biofilms, but whether biofilm susceptibility testing using
these higher drug concentrations results in improved clinical
outcomes remains to be determined (Chmiel 2014). It is diKicult for
an in vitro system to replicate all the complexities of the biofilm
environment in the CF lung and there is much that we do not
understand about how antibiotics work to make people with CF
better. In addition to their microbiological eKect, they may have
anti-inflammatory eKects that are not routinely measured (Wagner
2005).
Quality of the evidence
There was little risk of bias in either trial as the randomization
of participants was appropriately concealed and participants,
caregivers and investigators were blinded to the assignment.
Follow up was also adequate as outcomes measures were
obtained in the majority of randomized participants. In addition
to the methods, another strength of the Moskowitz trial was the
systematic way in which antibiotics were chosen in each group
(Moskowitz 2011). The investigators designed an algorithm to
calculate the conventional minimum inhibitory quotient and the
biofilm minimum inhibitory quotient of each drug based on the
achievable serum concentration divided by conventional or biofilm
minimum inhibitory concentrations, respectively. Antibiotics were
then chosen based on the highest quotient of each drug in
each class of antibiotics. This algorithm ensured a degree of
objectivity and reproducibility in the choice of antibiotics to treat
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P aeruginosa infections in individuals with CF, which can oLen
be a subjective process influenced by physician preferences and
various patient factors. Although the algorithm was complex, the
authors designed a publicly available computer-based model that
could be used by any treating physician, rendering the results
more generalizable (Moskowitz 2004). The Yau trial did not choose
antibiotics according to inhibitory quotients, but did follow a well-
described algorithm based on a previously published hierarchy of
antibiotics (Moskowitz 2005). In addition, all antibiotic regimens
for both arms of the trial were chosen in a blinded fashion by the
principal investigator, eliminating any bias introduced by multiple
prescribers (Aaron 2005). Finally, although biofilm antimicrobial
susceptibility testing was not shown to be superior to conventional
testing, it was at least as safe in both trials, with an equal number
of adverse events in each group, and as eKective, with comparable
decreases in sputum density and improvements in lung function,
as conventional testing.
The quality of the evidence provided by the two trials, and
assessed using the GRADE criteria, was deemed to be high for
two outcomes and moderate for the remaining four outcomes
presented in Summary of findings 1. The most common reason
for downgrading the evidence was due to imprecision from small
sample sizes, where only one trial could be included in the analysis.
For adverse events, the quality of the evidence was downgraded
due to imprecision again but due to low event rates.
Potential biases in the review process
There were no perceived biases in this review process.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The current evidence, limited to two trials, shows that there
is insuKicient evidence to recommend choosing antibiotics
based on biofilm antimicrobial susceptibility testing rather than
conventional antimicrobial susceptibility testing in the treatment
of Pseudomonas aeruginosa pulmonary infections in people with
cystic fibrosis (CF).
Implications for research
Although in vitro biofilm antimicrobial susceptibility systems
cannot currently predict better antibiotic choices for the treatment
of pulmonary infections in individuals with CF, biofilms are still
relevant given the known growth conditions of bacteria in CF lung.
Testing antimicrobials against bacterial biofilms in the laboratory
may be more appropriate in the development of newer, more
eKective formulations of drugs, able to penetrate CF sputum and
bacterial structures, which can then be tested in clinical trials.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Randomized, double-blind controlled clinical trial.
Multicenter: 7 centers in USA.
Participants randomized on the basis of results from either conventional or biofilm antimicrobial sus-
ceptibility testing of their P aeruginosa isolate cultured from the sputum obtained at the screening vis-
it.
Participants 39 participants with CF: biofilm-treated group (n = 20) and conventionally-treated (control) group (n =
19).
Mean (SD) age: biofilm group 32 (9.3) years; control group 28.2 (8.6) years.
Gender: biofilm group, 16 males and 4 females; control group, 9 males and 10 females.
Genotype delta F508 homozygous: biofilm group n = 11; control group n = 9.
Pancreatic insufficiency: biofilm group n = 18; control group n = 16.
Mean (SD) baseline FEV1 % predicted: biofilm group 62.2% (23.2); control group 64% (28.2).
Inclusion criteria: confirmed diagnosis of CF; 14 years of age or older; could spontaneously produce
sputum; able to perform pulmonary function tests; chronically infected with P aeruginosa; clinically
stable at the time of enrolment; provided written consent.
Exclusion criteria: sputum P aeruginosa density was < 105 CFU/g at screening; infected with BCC at
screening or in the previous 24 months; allergic to more than 2 classes of antibiotics; received a lung
transplantation; pregnant.
Interventions A 14-day course of any 2 antibiotics (IV or oral) chosen on the basis of results from either convention-
al or biofilm antimicrobial susceptibility testing of their P aeruginosa isolate cultured from the sputum
obtained at the screening visit.
Outcomes Primary outcome: microbiological response to antibiotic therapy, measured by the change in P aerug-
inosa sputum density, calculated as logarithm10 (log10) of end-of-treatment density minus log10 of
screening density in CFU/g.
Secondary outcomes: pulmonary response, measured as change in FEV1 L, calculated as end-of-treat-
ment FEV1 L minus the baseline FEV1 L.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants assigned to treatment groups using a block randomization proce-
dure, stratified by trial site, using computer-generated random numbers.
Allocation concealment
(selection bias)
Low risk Randomization assignments placed in numbered sealed envelopes which
were opened sequentially at the time of randomization by the statistician or
their designated representative. The remaining research staK, the participants
and their caregivers were unaware of the allocation.
Moskowitz 2011 
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Low risk The person responsible for participant care and the participant were aware of
the antibiotic choices but were blinded to the testing method (biofilm or con-
ventional) upon which this choice was based.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk The outcome assessor was aware of the antibiotic choices but was blinded





Low risk 39 participants randomized (20 to the biofilm-treated group, 19 to the conven-
tionally-treated (control) group).
1 participant randomized, but withdrawn prior to treatment and subsequently
re-randomized and treated.
Biofilm group: 2 withdrew prior to treatment; 1 discontinued treatment due to
adverse events.
Control group: 3 withdrew prior to treatment. 1 discontinued treatment due to
adverse events.
In the modified intent-to-treat analysis, 18 of the 20 participants in the biofilm
group and 16 of the 19 participants in the control group were analyzed. There-




Unclear risk Trial outcomes published in the original trial protocol on www.clinicaltrial-
s.gov (NCT00153634) were almost the same as the ones reported in the final
manuscript. Hospitalization data would likely be collected for safety issues
and so the lack of reporting for this outcome is not a risk of bias. However, for
lung function, the trial only reports results for FEV1, although we would expect
FVC and FEF25-75% to have been undertaken as part of the standard set of lung
function tests at clinic visits, hence unclear risk.





Methods Randomized, double-blind controlled clinical trial.
Multicenter: 5 CF centers in Canada.
Participants randomized at the time of a pulmonary exacerbation on the basis of results from either
conventional or biofilm antimicrobial susceptibility testing of their P aeruginosa isolate cultured from
the sputum obtained at the screening visit.
Participants Inclusion criteria: diagnosis of CF, chronic infection with P aeruginosa (> 50% of respiratory specimens
positive in the 24 months prior to screening) and the ability to produce sputum and to reproducibly
perform pulmonary function testing; provided written consent.
Exclusion criteria: sputum culture either negative for P aeruginosa or with a density of less than 105
CFU/mL at screening, history of B cepacia positive respiratory culture within 24 months prior to or at
screening, physician’s decision to use antibiotics other than those prescribed by the principal investi-
gator (VW), history of allergy to more than 2 classes of antibiotics or anaphylaxis to any antibiotic, sta-
tus post lung transplantation or listed for lung transplantation, pregnant or clinically unstable.
Yau 2014 
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39 participants with CF: biofilm-treated group (n = 24, 48 exacerbations) and the conventionally-treat-
ed (control) group (n = 15, 26 exacerbations).
Age: mean (range)
At first exacerbation: biofilm group 29.4 (11.3 to 49.2) years; control group 22.6 (10.1 to 53.2) years.
All exacerbations: biofilm group 27.2 (10.2 to 49.9) years; control group 20.3 (10.1 to 53.2) years.
Gender
At first exacerbation: biofilm group, 11 males and 13 females; control group, 3 males and 12 females.
All exacerbations: biofilm group, 22 males and 26 females; control group, 6 males and 20 females.
Genotype delta F508 homozygous
At first exacerbation: biofilm group n = 11 (48%); control group n = 9 (60%).
All exacerbations: biofilm group n = 26 (54%); control group n = 16 (61%).
CFRD
At first exacerbation: biofilm group n = 8 (33%); control group n = 3 (20%).
All exacerbations: biofilm group n = 12 (25%); control group n = 6 (23%).
Liver disease
At first exacerbation: biofilm group n = 3 (12%); control group n = 0 (0%).
All exacerbations: biofilm group n = 4 (8%); control group n = 0 (0%).
Pancreatic insufficiency:
At first exacerbation: biofilm group n = 22 (92%); control group n = 13 (87%).
All exacerbations: biofilm group n = 45 (97%); control group n = 24 (92%).
ABPA
At first exacerbation: biofilm group n = 3 (12%); control group n = 2 (13%).
All exacerbations: biofilm group n = 7 (14%); control group n = 5 (19%).
Baseline FEV 1 % predicted: mean (range)
At first exacerbation: in the biofilm group was 53.3% (26.8 to 83.9) and was 60.6% (25.2 to 98.3) in the
control group.
All exacerbations: in the biofilm group was 55.7% (25.6 to 111.3) and was 62.4% (25.2 to 98.3) in the con-
trol group.
Baseline FEV 1 L: mean (range)
At first exacerbation: in the biofilm group was 1.9 (0.8 to 3.7) and was 1.9 (0.7 to 3.7) in the control
group.
All exacerbations: in the biofilm group was 1.9 (0.8 to 4.2) and was 1.9 (0.7 to 3.7) in the control group.
At exacerbation FEV 1 % predicted: mean (range)
At first exacerbation: in the biofilm group was 41.8% (23.9 to 71.1) and was 52.9% (21.2 to 91.0) in the
control group.
All exacerbations: in the biofilm group was 45.0% (15.4 to 90.4) and was 53.1% (21.2 to 93.8) in the con-
trol group.
At exacerbation FEV 1 L: mean (range)
Yau 2014  (Continued)
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At first exacerbation: in the biofilm group was 1.4 (0.6 to 3.1) and was 1.7 (0.6 to 3.2) in the control
group.
All exacerbations: in the biofilm group was 1.5 (0.6 to 3.4) and was 1.7 (0.5 to 3.5) in the control group.
BMI (kg/m2) at baseline: mean (range)
At first exacerbation: in the biofilm group was 21.1 (14.6 to 30.1) and was 19.7 (14.2 to 26.8) in the con-
trol group.
All exacerbations: in the biofilm group was 20.6 (14.5 to 30.1) and was 19.2 (14.2 to 26.8) in the control
group.
BMI (kg/m2) at exacerbation: mean (range)
At first exacerbation: in the biofilm group was 20.6 (13.5 to 27.9) and was 18.8 (13.9 to 23.0) in the con-
trol group.
All exacerbations: in the biofilm group was 20.2 (13.5 to 27.9) and was 18.5 (13.9 to 23.7) in the control
group.
Maintenance treatment: dornase alfa
At first exacerbation: biofilm group n = 11 (46%); control group n = 7 (47%).
All exacerbations: biofilm group n = 28 (58%); control group n = 16 (61%).
Maintenance treatment: azithromycin
At first exacerbation: biofilm group n = 14 (58%); control group n = 4 (27%).
All exacerbations: biofilm group n = 11 (42%); control group n = 30 (62%).
Maintenance treatment: inhaled tobramycin
At first exacerbation: biofilm group n = 18 (75%); control group n = 12 (80%).
All exacerbations: biofilm group n = 36 (75%); control group n = 20 (77%).
Maintenance treatment: hypertonic saline
At first exacerbation: biofilm group n = 4 (17%); control group n = 2 (13%).
All exacerbations: biofilm group n = 11 (23%); control group n = 3 (11%).
Maintenance treatment: other inhaled antibiotics
At first exacerbation: biofilm group n = 2 (8%); control group n = 2 (13%).
All exacerbations: biofilm group n = 8 (17%); control group n = 5 (19%).
Interventions Two IV antibiotics chosen on the basis of results from either conventional or biofilm antimicrobial sus-
ceptibility testing of their P aeruginosa isolate cultured from their most recent sputum.
Outcomes Primary outcome: proportion of exacerbations in the biofilm versus conventional group in which a >
3 log10 drop in sputum density of P aeruginosa in CFU/mL from Day 0 to Day 14 of antibiotic treatment,
was achieved.
Secondary outcomes: pulmonary function tests (FEV1, FVC), CFQ-R, serum WBC, CRP, ESR and sputum




Bias Authors' judgement Support for judgement
Yau 2014  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Co-PI randomized participants according to a random numbers table generat-
ed for each site based on the expected number of PEx during the study period.
If a participant developed a second PEx during the study period they were re-




Low risk The method of selection (based on conventional or biofilm testing) was blind-
ed to all participants, the treating team and all study personnel with the ex-





Low risk "Although the actual antibiotics themselves were not blinded, the method of
selection (based on conventional or biofilm testing) was blinded to all sub-
jects, the treating team and all study personnel with the exception of co-PI YY
(who was not directly involved in any patient care)."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk "Although the actual antibiotics themselves were not blinded, the method of
selection (based on conventional or biofilm testing) was blinded to all sub-
jects, the treating team and all study personnel with the exception of co-PI YY




Low risk 41 participants randomised, 39 analysed, 2 (5%) excluded (one from each
group) with no data available for either of these. Reasons for exclusion given
- 1 from conventional group lost to follow up and 1 from biofilm group did not
grow P. aeruginosa on day 1.
Selective reporting (re-
porting bias)
Low risk Protocol accessed from clinicaltrials.gov, all outcomes listed in the protocol
are reported in the full paper.
Other bias Low risk No other potential sources of bias identified.
Yau 2014  (Continued)
B cepacia: Burkholderia cepacia
BCC: Burkholderia cepacia complex
CF: cystic fibrosis
CFQ-R: Cystic Fibrosis Questionnaire-Revised
CFU: colony forming units
Co-PI: co-primary investigator
CRP: C-reactive protein
ESR: erythrocyte sedimentation rate
FEF25-75%: mid-expiratory flow
FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
IV: intravenous
P aeruginosa: Pseudomonas aeruginosa
PEx: pulmonary exacerbation
WBC: white blood cell count
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aaron 2005 Trial of combination antibiotic susceptibility testing, not the topic of this review.
Oermann 2010 Trial of antibiotic susceptibility of P aeruginosa isolates after repeated courses of inhaled aztreon-
am lysine.
P aeruginosa: Pseudomonas aeruginosa
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W H A T ' S   N E W
 
Date Event Description
10 June 2020 New citation required but conclusions
have not changed
Two authors have joined the review team (SS and NJ) and SS has
taken the lead on the review.
Previous versions of this review were found to be noncompliant
with the Cochrane conflict of interest policy, which includes the
relevant parts of the Cochrane Commercial Sponsorship Policy,
by the Cochrane Funding Arbiters. This updated version of the re-
view is now compliant with the policy.
No new data have been included in this version of the review,
therefore our conclusions remain the same. Due to a lack of re-
search in this area, the review will not be updated until the au-
thors become aware of new research in the field.
10 June 2020 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders Review
Group's Cystic Fibrosis Trials Register identified four references
and online registry searches identified two references. One of the
references from the Cochrane Register search was a duplicate
of an additional reference to the included trial (Yau 2014); none
of the remaining references evaluated antimicrobial testing to
guide antibiotic therapy and therefore were not even listed as ex-
cluded in the current version of the review.
 
H I S T O R Y
Protocol first published: Issue 12, 2011
Review first published: Issue 11, 2012
 
Date Event Description
19 March 2020 Amended Clarification statement added from Alan Smyth, Co-ordinating
Editor on 19 March 2020: This review was found by the Cochrane
Funding Arbiters, post-publication, to be noncompliant with the
Cochrane conflict of interest policy, which includes the relevant
parts of the Cochrane Commercial Sponsorship Policy. The re-
view will be updated by August 2020; both authors of the future
update will be free of conflicts.
26 September 2017 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders Review
Group's Cystic Fibrosis Trials Register identified four new refer-
ences to an already included study (Yau 2014). No new studies
were identified in the searches of ongoing trials registries.
A summary of findings table has been added to the review.
26 September 2017 New citation required but conclusions
have not changed
No new data have been added to this update so our conclusions
remain the same.
25 February 2015 New citation required but conclusions
have not changed
Despite the inclusion of a new trial, our conclusions remain the
same.
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Date Event Description
25 February 2015 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders Group's Cystic
Fibrosis Trials Register identified three new references to a single
trial which was included in the review (Yau 2014). In the original
review, this trial had been identified and listed as ongoing.
 
C O N T R I B U T I O N S   O F   A U T H O R S
 
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draL the protocol Valerie Waters
Review stage: select which trials to include (2 + 1 ar-
biter)
Valerie Waters and Felix Ratjen (+ Nikki Jahnke)
Review stage: extract data from trials (2 people) Valerie Waters and Felix Ratjen
Review stage: enter data into RevMan Valerie Waters
Review stage: carry out the analysis Valerie Waters and Felix Ratjen
Review stage: interpret the analysis Valerie Waters and Felix Ratjen
Review stage: draL the final review Valerie Waters and Felix Ratjen
Update stage Valerie Waters, Felix Ratjen, Sherie Smith, Nikki Jahnke
NJ extracted data and assessed risk of bias for Yau 2014
Sherie Smith generated the Summary of Findings table and incorporated the
GRADE findings into the text of the review
 
D E C L A R A T I O N S   O F   I N T E R E S T
Two authors of this review (VW, FR) are investigators in the included biofilm trial which was funded by a grant from Innovotech Inc. and
the National Research Council Industrial Research Assistance Program (NRC-IRAP) of Alberta (Yau 2014). The funders had no involvement
in the trial design, interpretation of data, writing of the manuscript or decision to submit the manuscript for publication.
SS: none known.
VW: declares grant funding from Cystic Fibrosis Foundation, Cystic Fibrosis Canada, Canadian Institutes of Health Research and Gilead
Sciences. VW also declares consultancy fees from Tevapharm (who do not make anything related to antibiotic susceptibility testing).
NJ: none known.
FR: I have acted as a consultant to Novartis, Roche, Vertex, Boehringer Ingelheim, Bayer, Genentech. I have been paid for lectures by
Genentech. I have also received grants as PI for an early intervention study targeting Pseudomonas sponsored by Novartis and as PI for
other grants sponsored by Vertex. While I have received grants from Vertex, they do not produce antibiotics that would be eligible for
consideration in this review.
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External sources
• National Institute for Health Research, UK
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In a post hoc change the review authors additionally decided to report data as change from start of treatment and not just absolute values
for their primary outcome of lung function as these data are more useful to users of the review than just endpoint values which do not
relate to previous levels of lung function. Furthermore, a summary of findings table has been added in line with Cochrane guidance (2017)
and the final secondary outcome 'Use of oral antibiotics' has been removed since oral antibiotics are considered an antibiotic therapy
eligible for consideration following the testing (2020).
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